Notice2025-02507
Foreign-Trade Zone (FTZ) 7; Notification of Proposed Production Activity; Lilly del Caribe, Inc.; (Pharmaceutical Products); Carolina, Puerto Rico
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 12, 2025
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 28 (Wednesday, February 12, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 28 (Wednesday, February 12, 2025)]
[Notices]
[Page 9410]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-02507]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-6-2025]
Foreign-Trade Zone (FTZ) 7; Notification of Proposed Production
Activity; Lilly del Caribe, Inc.; (Pharmaceutical Products); Carolina,
Puerto Rico
Lilly del Caribe, Inc. submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Carolina, Puerto Rico, within Subzone 7K. The notification conforming
to the requirements of the Board's regulations (15 CFR 400.22) was
received on January 30, 2025.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product and material(s)/component(s) would be added to the production
authority that the Board previously approved for the operation, as
reflected on the Board's website.
The proposed finished product is finished orforglipron dosage form
(duty free).
The proposed foreign-status materials/components include
orforglipron active ingredient and orforglipron SDD (spray dried
dispersion) (duty rate is duty-free or 6.5%). Certain materials/
components are subject to duties under Section 1702(a)(1)(B) of the
International Emergency Economic Powers Act, depending on the country
of origin. The applicable section 1702 decision requires subject
merchandise to be admitted to FTZs in privileged foreign status (19 CFR
146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#690f1d13291d1b080d0c470e061f"><span class="__cf_email__" data-cfemail="8debf9f7cdf9ffece9e8a3eae2fb">[email protected]</span></a>. The closing period for their receipt is March 24, 2025.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#115578707f743f57787f6774635165637075743f767e67"><span class="__cf_email__" data-cfemail="7d39141c1318533b14130b180f3d090f1c1918531a120b">[email protected]</span></a>.
Dated: February 6, 2025.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2025-02507 Filed 2-11-25; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 12, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.